MetaTrader
  • Mercati
  • Grafici & Idee
  • Algo
  • Notizie
  • Store
  • Broker
  • Scarica
  • Calendario Economico
  • Segnali di Trading
  • Terminale Web
  • English English
  • Русский Русский
  • 中文 中文
  • Español Español
  • Português Português
  • 日本語 日本語
  • Deutsch Deutsch
  • 한국어 한국어
  • Français Français
  • Türkçe Türkçe
Axsome Therapeutics, Inc

AXSM

#862
Axsome Therapeutics, Inc
163.8900
+1.83%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
163.8900
163.8900
Intervallo Annuale
123.5000
191.5000
Variazione giornaliera
+1.83%
Variazione Mensile
-12.68%
Variazione di 6 mesi
+25.88%
Variazione Annuale
+25.88%
Chiusura Precedente
160.9500
Open
163.8900
Bid
Ask
Low
163.8900
High
163.8900
Volume
137
  1. Mercati
  2. Mercato Azionario Statunitense
  3. Salute
  4. AXSM
Open full chart

Financials

Overview Estratto Conto Statistics Dividends
Quarterly Annual
Value 202020212022202320242025 TTM

Notizie

Investor's Business Daily Investor's Business Daily
NVDA NVO SNOW CRM WDAY
ieri, 16:04
Stock Market Can't Hold Key Levels Amid AI Concerns; Nvidia Tumbles Despite Strong Earnings: Weekly Review
Investor's Business Daily Investor's Business Daily
ROAD FNV AEM EQX TARS
2026.02.24
Construction Star Leads 11 Hot Stocks To Various Best Growth Lists like IBD 50, Sector Leaders
Zacks Zacks
JAZZ AXSM CSTL HRMY
2026.02.24
AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
Investing Investing
AXSM
2026.02.24
UBS alza il target su Axsome Therapeutics per l’espansione della forza vendita
Investing Investing
AXSM
2026.02.24
UBS raises Axsome Therapeutics stock price target on sales force expansion
Investing Investing
AXSM
2026.02.24
Wolfe Research avvia la copertura su Axsome con rating outperform
Investing Investing
AXSM
2026.02.24
Wolfe Research initiates Axsome stock with outperform rating
Investing Investing
AXSM
2026.02.24
RBC Capital alza il target su Axsome Therapeutics dopo i risultati
Investing Investing
AXSM
2026.02.24
RBC Capital raises Axsome Therapeutics price target on earnings
Investing Investing
AXSM
2026.02.24
Axsome somministra il primo paziente nello studio sulla depressione con solriamfetol
Investing Investing
AXSM
2026.02.24
Axsome doses first patient in depression trial with solriamfetol
Investing Investing
AXSM
2026.02.24
Guggenheim alza il target di Axsome a 220$ su vendite solide

Mercati

  • Mercato Azionario Americano
  • Valute
  • Criptovalute
  • Metalli
  • Materie Prime

Grafici & Idee

  • Idee di Trading
  • Idee Educative
  • Grafici

MQL5 Community

  • Market
  • Segnali
  • Forum
  • Articoli
  • CodeBase

Notizie

  • Mercato Azionario Americano
  • Valute
  • Criptovalute
  • Metalli
  • Materie Prime

Broker

  • Tutti i Broker
  • Forex
  • Azioni
  • Metalli
MetaTrader 5
MQL5 Channels
Economic Calendar
Esclusione di Responsabilità e Informativa sui Rischi Termini di Utilizzo Contatti e richieste Legale
Copyright 2000-2026, MetaQuotes Ltd